Zevra Joins Sleep Data Initiative As Founding Member
Zevra says data from its clinical program for its drug candidate to treat idiopathic hypersomnia will aid the development of treatments for rare sleep disorders through the platform.
Zevra says data from its clinical program for its drug candidate to treat idiopathic hypersomnia will aid the development of treatments for rare sleep disorders through the platform.
Harmony Biosciences has initiated a phase 3 trial evaluating the efficacy and safety of pitolisant in adults with idiopathic hypersomnia.
A common concern in narcolepsy and idiopathic hypersomnia is a feeling of having little control over symptoms, which can lead to despair. But disorders of excessive sleepiness do have both medication and non-medication treatment approaches.
Thirteen abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021.
Read MoreIdiopathic hypersomnia is a chronic neurologic sleep disorder that causes excessive daytime sleepiness even though a person can get adequate, or more typically, long amounts of sleep.
Read MoreThe AAN presentation further quantifies the previously reported Phase 3 top-line results.
Read MoreKemPharm is investigating “KP1077” as a potential treatment for idiopathic hypersomnia (IH), a sleep disorder of excessive sleepiness.
Read MoreEmory University researchers find that functional imaging of the brain could shed light on the underlying disease states in hypersomnolence disorders.
Read More“There is significant need for greater awareness of idiopathic hypersomnia, which can severely impact a person’s daily life, and can often be misdiagnosed or undiagnosed over a substantial period of time.”
Read MoreThe Hypersomnia Foundation, a nonprofit patient advocacy group dedicated to improving the lives of people with idiopathic hypersomnia and other rare sleep disorders, has chosen the first recipient of its new Research Award...
Read MoreOver 4 years, narcolepsy prevalence in claims data increased 13.8% and IH prevalence 33.8%. By...
Read MoreResearchers input MSLT and preceding PSG data, then report on the results. By Yoona Ha In recent...
Read MoreResearchers investigate how timing and density of EEG segments differ among patients with...
Read MoreJazz Pharmaceuticals plc has enrolled the first patient in a phase 3 clinical trial evaluating the efficacy and safety of JZP-258 for the treatment of idiopathic hypersomnia. JZP-258 is an investigational oxybate mixed-salts...
Read MoreNarcolepsy type 1 is distinct from other hypersomnias in several ways. People diagnosed with it must have sleepiness and either objectively low levels orexin or cataplexy and a positive multiple sleep latency test.
Read MoreThe 5th annual international Idiopathic Hypersomnia Awareness Week runs from Sept 4 to 10; the 2017 focus is “research changes lives.” Idiopathic hypersomnia is a neurological sleep/wake disorder. It can cause a...
Read MoreThe Hypersomnia Foundation board of directors recently announced the launch of the Hypersomnia Foundation’s Registry at CoRDS (Coordination of Rare Diseases at Sanford). In its e-newsletter, the Hypersomnia Foundation states:...
Read MoreResearchers find a significant positive correlation between self-reported daytime sleepiness and attention problems for adult patients with narcolepsy and idiopathic hypersomnia, with both genders being affected equally.
Read More